 BEVERLY Hills, Calif., May 18, 2021 PRNewswire -- GT Biopharma, Inc. NASDAQ: GTBP a clinical stage biopharmaceutical company focused on the development and commercialization of disruptive, target-directed Natural Killer NK cell engager immunotherapy protein biologic platform technology, TriKETM, for the treatment of cancer and infectious diseases, today announced that it will be hosting a call with Dr. Jeffrey S. 